IRADIMED Resultados de beneficios anteriores

Pasado controles de criterios 5/6

IRADIMED ha aumentado sus beneficios a una tasa media anual de 22.1%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.5% anual. Los ingresos han ido creciendo a una tasa media de 15% al año. La rentabilidad financiera de IRADIMED es de 24.1%, y sus márgenes netos son de 26.2%.

Información clave

23.9%

Tasa de crecimiento de los beneficios

20.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	15.7%
Rentabilidad financiera	23.5%
Margen neto	26.5%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture

Jul 13

iRadimed EPS beats by $0.04, beats on revenue

Apr 30

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero IRADIMED. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:IRMD Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	68	18	28	3
31 Dec 23	66	17	27	3
30 Sep 23	63	16	26	3
30 Jun 23	60	15	25	3
31 Mar 23	56	14	25	3
31 Dec 22	53	13	23	2
30 Sep 22	50	13	23	2
30 Jun 22	48	12	22	2
31 Mar 22	45	10	21	2
31 Dec 21	42	9	20	2
30 Sep 21	38	6	17	2
30 Jun 21	35	5	17	2
31 Mar 21	32	1	19	2
31 Dec 20	32	1	20	2
30 Sep 20	34	4	23	2
30 Jun 20	36	5	23	2
31 Mar 20	39	10	20	1
31 Dec 19	39	10	20	1
30 Sep 19	36	8	18	1
30 Jun 19	34	8	17	1
31 Mar 19	32	7	16	1
31 Dec 18	30	6	16	2
30 Sep 18	29	5	15	1
30 Jun 18	27	3	15	2
31 Mar 18	25	2	15	2
31 Dec 17	23	0	15	2
30 Sep 17	22	1	14	2
30 Jun 17	24	3	13	2
31 Mar 17	29	5	14	2
31 Dec 16	32	7	14	1
30 Sep 16	35	8	15	1
30 Jun 16	35	9	14	2
31 Mar 16	33	8	13	2
31 Dec 15	31	8	12	2
30 Sep 15	26	5	11	2
30 Jun 15	22	4	10	1
31 Mar 15	19	3	9	1
31 Dec 14	15	2	8	1
30 Sep 14	15	2	7	1
30 Jun 14	14	2	6	1
31 Mar 14	12	2	5	1
31 Dec 13	11	2	5	1

Ingresos de calidad: IRMD tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio (26.2%) de IRMD son superiores a los del año pasado (24.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lIRMD han crecido significativamente en un 22.1% al año.

Acelerando crecimiento: El crecimiento de los beneficios de IRMD en el último año (34%) supera su media de 5 años (22.1% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de IRMD en el último año (34%) superó al de la industria Medical Equipment 3.3%.

IRADIMED Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Upcoming dividend of US$0.15 per share

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

Now 25% overvalued

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations

Independent Director notifies of intention to sell stock

COO, CFO & Secretary recently sold US$965k worth of stock

Investor sentiment improved over the past week

Desglose de ingresos y gastos
Beta